Kevin F. Mclaughlin

This profile gathers the share dealings of Kevin F. Mclaughlin across 4 companies, led by Acceleron Pharma Inc, Vericel Corp and Decibel Therapeutics, Inc. We count 54 filings; the first trade dates from 2 January 2020 and the latest from 12 August 2026.

The open-market side counts 1 purchase for €108k alongside 15 sales for €10.1M. Netting one side against the other leaves €10.0M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 share grants and 34 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

On 14 August 2026 came the latest disclosure, an option exercise for €79k in Vericel Corp. The most recent open-market purchase was published on 20 November 2025, 337 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.